Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN1A | P35498 | 4/20 | 0.53 |
| ▸ | SCN2A | Q99250 | 4/20 | 0.53 |
| ▸ | SCN3A | Q9NY46 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.51 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.51 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28532026 | 0.98 | KMT2A (0.56) | SCN1ASCN2ASCN3AKMT2AMEN1 | |
| SCHEMBL1818116 | 0.94 | SCN1A (0.49) | SCN1ASCN2ASCN3AKMT2AMEN1 | |
| SCHEMBL18687104 | 0.91 | SCN1A (0.50) | SCN1ASCN2ASCN3AKMT2AMEN1 | |
| SCHEMBL1818115 | 0.87 | SCN1A (0.47) | SCN1ASCN2ASCN3AKMT2AMEN1 | |
| SCHEMBL23199841 | 0.86 | CHRM4 (0.54) | SCN1ASCN2ASCN3AKMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL23199820 | 0.85 | SMN1; SMN2 (0.53) | SCN1ASCN2ASCN3AKMT2AMEN1 | |
| SCHEMBL9330353 | 0.84 | SCN1A (0.49) | SCN1ASCN2ASCN3AKMT2AMEN1 | |
| SCHEMBL18195619 | 0.84 | CHRM3 (0.45) | SCN1ASCN2ASCN3AKMT2AMEN1 | |
| SCHEMBL12879857 | 0.84 | SCN1A (0.45) | SCN1ASCN2ASCN3AKMT2AMEN1 | |
| SCHEMBL14476943 | 0.84 | SCN1A (0.45) | SCN1ASCN2ASCN3AKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210253626-A1 | PRODRUGS OF FULVESTRANT | KI PHARMACEUTICALS, LLC | 2021-08-19 | — | — | US | disclosed |
| EP-3801553-A2 | PRODRUGS OF FULVESTRANT | Kashiv Biosciences, LLC (US) | 2021-04-14 | — | — | EP | disclosed |
| CN-110156763-B | Posaconazole derivative, pharmaceutical composition and application thereof | 北京国鸿生物医药科技有限公司 | 2021-03-23 | — | — | CN | disclosed |
| EP-1602362-B1 | DRUG COMPOSITION HAVING ACTIVE INGREDIENT ADHERED AT HIGH CONCENTRATION TO SPHERICAL CORE | TAKEDA PHARMACEUTICAL (JP) | 2016-09-28 | — | — | EP | disclosed |
| EP-2275088-B1 | Method for producing granules | TAKEDA PHARMACEUTICAL (JP) | 2015-09-02 | — | — | EP | disclosed |
| EP-2275088-A2 | Method for producing granules | Takeda Pharmaceutical Company Limited (JP) | 2011-01-19 | — | — | EP | disclosed |
| EP-1852100-A1 | METHOD FOR PRODUCING GRANULES | Takeda Pharmaceutical Company Limited (JP) | 2007-11-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253626-A1 | PRODRUGS OF FULVESTRANT | CYP19A1, PGR, CYP21A2 | SCN1A 4596/4885SCN2A 3668/4885SCN3A 4573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.